Supriya Lifescience gets CEP for anti-histamine therapy from EDQM; Stock soars 3%

29 Sep 2022 , 09:18 AM

Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines and HealthCare (EDQM) has granted Certification of Suitability (CEP) for Diphenhydramine Hydrochloride, API in AntiHistamine therapy.

In a regulatory filing, the company said that this will be an added advantage for the company in the European market. Global demand for Diphenhydramine Hydrochloride is 1850 tons, of which major demand is in the regulated markets.

At around 9:18 AM, Supriya Lifescience Ltd is currently trading at Rs305.35 per share up by Rs9 or 3.04% from its previous closing of Rs296.35 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]